Page last updated: 2024-12-05
fomblin y 04
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
fomblin Y 04: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 13350568 |
| SCHEMBL ID | 198 |
| MeSH ID | M0071510 |
Synonyms (15)
| Synonym |
|---|
| 1,1,1,2,3,3-hexakis(fluoranyl)propan-2-ol |
| A844141 |
| 1,1,1,2,3,3-hexafluoro-2-propanol |
| hexafluoro-2-propylalcohol |
| fomblin y-04 |
| fomblin y 04 |
| AKOS015995331 |
| SCHEMBL198 |
| 33701-74-5 |
| AMY3633 |
| nmfqpfsipwzzmr-uhfffaoysa-n |
| hexafluoro-i-propanol |
| hexafluoropropan-2-ol |
| DTXSID301300789 |
| 85592-84-3 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Because the possible toxicological relevance of the temporarily increased motor activity observed in 1000 mg/kg/d males could not be excluded, these changes were considered possibly adverse in nature." | ( A Combined 28-Day Oral Toxicity Study of HFPO-Amidol (CASRN 75888-49-2) With Reproductive/Developmental Toxicity Screening Test in Wistar Han Rats. Bagley, BD; Hakes, DC; Hope, EF; Moilanen, LH; Reynolds, JE; van Otterdijk, F, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The changes observed in female rats were considered not treatment related in the absence of a dose-response trend." | ( A Combined 28-Day Oral Toxicity Study of HFPO-Amidol (CASRN 75888-49-2) With Reproductive/Developmental Toxicity Screening Test in Wistar Han Rats. Bagley, BD; Hakes, DC; Hope, EF; Moilanen, LH; Reynolds, JE; van Otterdijk, F, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||